cellectis

Cellectis Gains FDA Approval for Testing New Gene-Edited Cancer Treatment

Feb 7, 2017 Cellectis, the Paris-based biotech, has received an Investigational New Drug, or IND, approval from the U.S. Food and Drug Administration (FDA) for conducting phase I clinical trials with UCART123, the gene-edited product candidate of the biotech, in patients with acute myeloid leukemia, or AML, and blastic plasmacytoid dendritic cell neoplasm, or BPDCN. This is … Continue reading Cellectis Gains FDA Approval for Testing New Gene-Edited Cancer Treatment

Advertisements
astrazeneca

AstraZeneca expands opportunities for 1st-line lung cancer Immuno-Oncology program

17 January 2017 AstraZeneca has provided an update on its Immuno-Oncology (IO) late-stage clinical development program in 1st-line non-small cell lung cancer (NSCLC), including a refinement of the Phase III MYSTIC trial. The MYSTIC trial was initially designed to assess the benefit of durvalumab monotherapy and durvalumab and tremelimumab (durva + treme) combination therapy versus standard-of-care (SoC) … Continue reading AstraZeneca expands opportunities for 1st-line lung cancer Immuno-Oncology program

Eisai

Eisai plots new drug applications in US, Europe and China after Lenvima scores in head-to-head liver cancer study

January 25, 2017 Eisai says that its can­cer drug Lenvima (lenva­tinib) hit the pri­mary end­point in a Phase III study for the treatment of liver can­cer, prov­ing non-in­fe­rior to Nex­avar. That suc­cess will set up reg­u­la­tory fil­ings in the US, Eu­rope and Asia, the com­pany adds. Liver can­cer is a par­tic­u­larly big prob­lem in China, where Eisai … Continue reading Eisai plots new drug applications in US, Europe and China after Lenvima scores in head-to-head liver cancer study

bristol-calithera

BMS and Calithera Announce Clinical Collaboration to Evaluate nivolumab in combination with CB-839 for Renal Cell Carcinoma

December 21, 2016 Bristol-Myers Squibb Company and Calithera Biosciences, Inc., a clinical stage biotechnology company focused on discovering and developing new small molecule drugs directed against tumor metabolism and tumor immunology targets for treating cancer, have announced a clinical trial collaboration to evaluate the Opdivo of Bristol-Myers Squibb in combination with  CB-839 of Calithera in patients with … Continue reading BMS and Calithera Announce Clinical Collaboration to Evaluate nivolumab in combination with CB-839 for Renal Cell Carcinoma

Fastest Growing Pharmaceutical Classes Today and Beyond - Igeahub.com

Fastest Growing Pharmaceutical Classes Today and Beyond

With the increasing prevalence of different health conditions requiring expensive lifelong treatment, the global sales of therapeutics have been expected to skyrocket in the coming years. In the year 2015, pharmaceutical spending in the United States has reached 1 112.2 USD per capita. This covers expenditures on both prescription medicines as well as self-medication or … Continue reading Fastest Growing Pharmaceutical Classes Today and Beyond

Celgene Logo

ABOUND Data Explores Safety and Efficacy of ABRAXANE® for the Treatment of Patients with Lung Cancer

Dec 6, 2016 Celgene Corporation has announced interim results from the ABOUND clinical trial program evaluating the use of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in patients with advanced non-small cell lung cancer (NSCLC). Interim data presented from the ABOUND trials during the IASLC 17th World Conference on Lung Cancer (WCLC) reinforces the benefit of ABRAXANE/carboplatin doublet … Continue reading ABOUND Data Explores Safety and Efficacy of ABRAXANE® for the Treatment of Patients with Lung Cancer

Celgene Logo

Positive Results Found in the Use of ABRAXANE® as First-Line Treatment of Metastatic Triple Negative Breast Cancer

The results of Celgene’s randomized phase II tnAcity trial of ABRAXANE® for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) were presented at the 2016 San Antonio Breast Cancer Symposium (SABCS) in December 6-10, 2016. The trial found that an investigational weekly combination regimen of ABRAXANE + carboplatin had significantly longer progression-free survival (PFS) (7.4 months) … Continue reading Positive Results Found in the Use of ABRAXANE® as First-Line Treatment of Metastatic Triple Negative Breast Cancer

Roche logo

Roche launches a global network of cancer immunotherapy centers of research excellence (imCORE™)

15 November 2016 Roche has launched the global network of cancer immunotherapy Centers of Research Excellence (imCORE™), which will bring together many of the world’s leading scientific and clinical experts in cancer immunotherapy for collaborating in the investigation of the most promising new treatment approaches. The target is to start pre-clinical and clinical research rapidly … Continue reading Roche launches a global network of cancer immunotherapy centers of research excellence (imCORE™)

Pfizer logo

European Union Gives Approval to IBRANCE® (palbociclib) for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer

November 10, 2016 Pfizer Inc. has announced that the European Commission (EC) has approved IBRANCE® (palbociclib) for treating women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer. The approval is for IBRANCE for using in combination with an aromatase inhibitor. It also covers the use of IBRANCE combining … Continue reading European Union Gives Approval to IBRANCE® (palbociclib) for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer

bristol-enterome

Bristol-Myers Squibb and Enterome Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Bioactive Molecules, and Drug Targets

November 16, 2016 Bristol-Myers Squibb Company and Enterome, a pioneer in developing pharmaceuticals and diagnostics based on the gut microbiome, announced that they have entered into an Immuno-Oncology focused collaboration agreement for discovering and developing microbiome-derived biomarkers, bioactive molecules, and drug targets. These will be developed as potential companion diagnostics and therapeutics for cancer. Furthermore, through this … Continue reading Bristol-Myers Squibb and Enterome Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Bioactive Molecules, and Drug Targets